Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Belantamab mafodotin (GSK2857916) is a conjugate of a humanized, targeted monoclonal antibody directed against the B cell maturation antigen (BCMA) and the cytotoxic agent McMMAF, exhibiting anti-myeloma activity [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Belantamab mafodotin (GSK2857916) is a conjugate of a humanized, targeted monoclonal antibody directed against the B cell maturation antigen (BCMA) and the cytotoxic agent McMMAF, exhibiting anti-myeloma activity [1] [2]. |
In vitro | Belantamab mafodotin exhibits a high affinity for the human BCMA protein, as indicated by a dissociation constant (K d) of 1 nM [2]. Additionally, it triggers a G2/M phase arrest in multiple myeloma cells, with the extent of the effect dependent on both concentration and exposure duration [2]. Furthermore, belantamab mafodotin significantly enhances the phagocytosis of multiple myeloma cells by macrophages derived from macrophage colony-stimulating factor (M-CSF) stimulated monocytes [2]. |
In vivo | Belantamab mafodotin significantly enhances survival relative to the vehicle in mice with OPM2 tumors [2]. |
Synonyms | Belantamab mafodotin-blm, GSK2857916 |
Molecular Weight | N/A |
CAS No. | 2050232-20-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Belantamab mafodotin 2050232-20-5 Belantamab mafodotin-blm GSK-2857916 GSK2857916 GSK 2857916 inhibitor inhibit